Miscellaneous Dermatological Conditions
A previous Phase 2 trial of 17 patients with EBS showed that 60% of those treated with diacerein cream experienced at least a 40% reduction in blistering after 4 weeks vs 18% on vehicle.
The multicenter retrospective study (N=377) was conducted to investigate the causes, treatment protocols, and mortality rates of US adults with SJS/TEN.
Evaluators were able to match the correct 3-D nose to the corresponding volunteers' photographs in 171 of 175 photographs (97.7%).
The researchers found that the mean time to clinical resolution was 9 days with teledermoscopy referral, compared with 35 days with usual care alone.
Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.
The researchers found that at 4 weeks and 4 months there were significant differences in physician rater assessment for visual detection and palpability between saline and hyaluronidase; this was mirrored by participant self-assessment at 4 weeks and 4 months.
The decreases from baseline using visual analogue scale pruritus scores were statistically significantly larger with the 1- and 5-mg doses of serlopitant (P=.022 and .013, respectively) versus placebo at week 6.
"Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents," the authors write.
The average time to additional treatment was 35.7 days. Adverse effects included bruising, contour irregularities, swelling, and Tyndall effect, and these occurred in 10, 2, 3, and 1% of patients, respectively.
The researchers found that among 78 identified patients over a 7-year period, complications were seen following abdominoplasty (35 procedures), breast augmentation (25), and foreign body injections (15).
The researchers found that overall repigmentation was significantly higher in the patches treated with 5-fluorouracil compared with tacrolimus. Excellent improvement was seen in 48% of the 5-fluorouracil-treated patches versus 16% of tacrolimus-treated patches.
"Excess facial or body hair is not only distressing to women, it is often a symptom of an underlying medical problem," said Kathryn Martin, MD, Massachusetts General Hospital and lead author of the study.
The researchers found that 34.2% of participants experienced sunburn in 2015. The prevalence was higher among younger age groups (51.2% for those aged 18 to 29 years) and in non-Hispanic whites and those with sun-sensitive skin (42.5 and 50.2%, respectively).
The researchers found that, based on the 14 patients who completed the study, the visual analogue scale score and scar width measurements showed a significant improvement in appearance and narrower scars for the halves of the scars treated with botulinum toxin type A (P=0.046 and 0.001, respectively).
Both Calm topical and Calm + Detox supplements do not contain any steroids, parabens, sulfates, preservatives, petroleum, tree nuts, and gluten.
Among patients admitted to the hospital for a provisional diagnosis of cellulitis, early dermatologic consultation was associated with improved recognition of pseudo-cellulitis, decreased antibiotic use, and earlier discharge.
The researchers found that compared to baseline assessments, both treatments showed a statistically significant improvement based on physician clinical assessment, skin hydration, transepidermal water loss, and patient-assessed visual analog scale following 2 and 4 weeks of treatment.
The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.
In December, a Phase 3, randomized, double-blind, placebo-controlled trial (JADE) was initiated to evaluate the safety and efficacy of PF-04965842 in 375 patients aged ≥12 years with moderate to severe AD.
The remaining 3 patients had well-controlled disease after omalizumab treatment. In 30% of patients, the best response to omalizumab was achieved after interval administration of a 9-day course of methylprednisolone (total dose of 188mg)
A total of 7 trials involving 346 patients were identified; nitroglycerin ointments were used in 4 trials, MQX-503 in 2 trials, and a compounded nitrite in 1 trial.
The researchers found that, over 7 years of follow-up, there was significant sustained improvement in skin score as well as in vasculopathy and gastrointestinal manifestations.
The fibronectin-stained area from skin biopsies was significantly higher in both groups after treatment compared with before, and it was significantly higher after carboxytherapy compared to PRP.